Recent clinical advances with chimeric antigen receptor (CAR) T cells have led to the accel-erated clinical approval of CD19-CARs to treat acute lymphoblastic leukemia. The CART cell therapy is nevertheless associated with toxicities, especially if the CARs...
Other documents